A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S (R) in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation
M. Oberbaum et al., A randomized, controlled clinical trial of the homeopathic medication TRAUMEEL S (R) in the treatment of chemotherapy-induced stomatitis in children undergoing stem cell transplantation, CANCER, 92(3), 2001, pp. 684-690
BACKGROUND. Stomatitis is a common consequence of chemotherapy and a condit
ion for which there is little effective treatment. Although the management
of patients with other chemo therapy-related toxicities has improved in rec
ent years, the incidence of stomatitis is increasing because of more intens
ive treatment and is often a dose limiting factor in chemotherapy. The auth
ors assessed the efficacy of a homeopathic remedy, TRAUMEEL S(R), in the ma
nagement of chemotherapy-induced stomatitis in children undergoing bone mar
row transplantation.
METHODS. A randomized, placebo-controlled, double-blind clinical trial was
conducted in 32 patients ages 3-25 years who had undergone allogeneic (16 p
atients) or autologous (16 patients) stem cell transplantation. Of the 30 e
valuable patients, 15 were assigned placebo, and 15 were assigned TRAUMEEL
S both as a mouth rinse, administered five times daily from 2 days after tr
ansplantation for a minimum of 14 days, or until at least 2 days after all
signs of stomatitis were absent. Stomatitis scores were evaluated according
to the World Health Organization grading system for mucositis.
RESULTS. A total of five patients (33%) in the TRAUMEEL S treatment group d
id not develop stomatitis compared with only one patient (7%) in the placeb
o group. Stomatitis worsened in only 7 patients (47%) in the TRAUMEEL S tre
atment group compared with 14 patients (93%) in the placebo group. The mean
area under the curve stomatitis scores were 10.4 in the TRAUMEEL S treatme
nt group and 24.3 in the placebo group, This difference was statistically s
ignificant (P < 0.01).
CONCLUSIONS. This study indicates that TRAUMEEL S may reduce significantly
the severity and duration of ch emo therapy-induced stomatitis in children
undergoing bone marrow transplantation. Cancer 2001;92:684-90. (C) 2001 Ame
rican Cancer Society.